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To Target or Not to Target, That Is
the Question
TO THE EDITOR: Ramalingam et al1 recently reported the
interesting results achieved with dacomitinib (PF-00299804), a
pan– human epidermal growth factor receptor (HER) inhibitor.
The authors demonstrated that dacomitinib was able to selec-
tively, irreversibly (covalently) bind to the adenosine triphos-
phate domain of each of the three kinase-active members of the
HER family: epidermal growth factor receptor (EGFR)/HER1,
HER2, and HER4. In addition, dacomitinib demonstrated sig-
nificantly improved progression-free survival compared with
erlotinib in the treatment of non–small-cell lung cancer,
with acceptable toxicity. The authors concluded that the
progression-free survival benefit was observed in most clinical
and molecular subsets, notably KRAS wild-type/EGFR any sta-
tus, KRAS wild-type/EGFR wild-type, and EGFR mutants.
In this phase II trial, which was not powered for subgroup
analysis, it is important to note that the significant imbalance
(20.2% v 11.7%) in EGFR mutations in favor of dacomitinib
may be principally responsible for the overall positive results. In
fact, patients with EGFR mutations shift the risk of progression
from a reduction of 34% to 30%, rendering the overall results
not statistically significant. Similar results, also not statistically
significant, are found if we consider only the subgroup of pa-
tients with wild-type EGFR mutations. However, an interesting
benefit in wild-type EGFR mutations can be hypothesized, pos-
sibly driven by other biomarkers, such as the overexpression of
HER2 or the activation of the phosphatidylinositol 3-ki-
nase pathway.2,3
We agree that dacomitinib is an interesting drug, but its develop-
ment should not be in an unselected patient population. Today, a
target agent must be used for a particular target to avoid another “me
too” drug for unselected patients.
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